Determination of the peptide binding motif and high-affinity ligands for HLA-DQ4 using synthetic peptide libraries

Human Immunology

Volumn 65, Issue 6, 2004, Pages 594-601

  Volz, Thomas ^a   Schwarz, Gerold ^b   Fleckenstein, Burkhard ^e   Schepp, Carsten P ^a   Haug, Markus ^a   Roth, Johannes ^d   Wiesmüller, Karl Heinz ^c   Dannecker, Günther E ^a,f  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c EMC MICROCOLLECTIONS GMBH   (Germany)

^d HUMBOLDT UNIVERSITY   (Germany)

^e OSLO UNIVERSITY HOSPITAL   (Norway)

^f OLGAHOSPITAL   (Germany)

Author keywords

high affinity ligands; HLA DQ; juvenile idiopathic arthritis; peptide binding motif; peptide library

Indexed keywords

AMINO ACID; HLA ANTIGEN; HLA DQ4 ANTIGEN; HLA DQ7 ANTIGEN; NONAPEPTIDE; PEPTIDE; PEPTIDE LIBRARY; UNCLASSIFIED DRUG;

ACETYLATION; AMINO ACID SEQUENCE; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; HUMAN; HUMAN CELL; JUVENILE RHEUMATOID ARTHRITIS; LIGAND BINDING; PATHOGENESIS; PEPTIDE ANALYSIS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DETERMINATION; PROTEIN MOTIF; SCREENING;

AMINO ACID MOTIFS; AMINO ACID SEQUENCE; ARTHRITIS, JUVENILE RHEUMATOID; CELL LINE, TRANSFORMED; HLA-DQ ANTIGENS; HUMANS; LIGANDS; MOLECULAR SEQUENCE DATA; PEPTIDE LIBRARY; PEPTIDES; PROTEIN BINDING;

EID: 3042669414     PISSN: 01988859     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.humimm.2004.02.027     Document Type: Article

References (33)

1. Germain R.N. MHC-dependent antigen processing and peptide presentation providing ligands for T lymphocyte activation. Cell. 76:1994;287
2. Stern L.J., Brown J.H., Jardetzky T.S., Gorga J.C., Urban R.G., Strominger J.L., Wiley D.C. Crystal structure of the human class II MHC protein HLA-DR1 complexed with an influenza virus peptide. Nature. 368:1994;215
3. Rammensee H.G., Friede T., Stevanović S. MHC ligands and peptide motifs first listing. Immunogenetics. 41:1995;178
4. Petty R.E., Southwood T.R., Baum J., Bhettay E., Glass D.N., Manners P., Maldonado-Cocco J., Suarez-Almazor M., Orozco-Alcala J., Prieur A.M. Revision of the proposed classification criteria for juvenile idiopathic arthritis Durban, 1997. J Rheumatol. 25:1998;1991
5. Albert E.D., Scholz S. Juvenile arthritis genetic update. Baillieres Clin Rheumatol. 12:1998;209
6. Haas J.P., Nevinny-Stickel C., Schoenwald U., Truckenbrodt H., Suschke J., Albert E.D. Susceptible and protective major histocompatibility complex class II alleles in early-onset pauciarticular juvenile chronic arthritis. Hum Immunol. 41:1994;225
7. Thomson W., Barrett J.H., Donn R., Pepper L., Kennedy L.J., Ollier W.E., Silman A.J., Woo P., Southwood T. Juvenile idiopathic arthritis classified by the ILAR criteria HLA associations in UK patients. Rheumatology (Oxford). 41:2002;1183
8. Ihle J., Fleckenstein B., Terreaux C., Beck H., Albert E.D., Dannecker G.E. Differential peptide binding motif for three juvenile arthritis associated HLA-DQ molecules. Clin Exp Rheumatol. 21:2003;257
9. Pinilla C., Appel J.R., Blanc P., Houghten R.A. Rapid identification of high affinity peptide ligands using positional scanning synthetic peptide combinatorial libraries. Biotechniques. 13:1992;901
10. Ziegler A., Heinig J., Muller C., Gotz H., Thinnes F.P., Uchanska-Ziegler B., Wernet P. Analysis by sequential immunoprecipitations of the specificities of the monoclonal antibodies TU22, 34, 35, 36, 37, 39, 43, 58 and YD1/63. HLK directed against human HLA class II antigens. Immunobiology. 171:1986;77
11. Gorga J.C., Horejsi V., Johnson D.R., Raghupathy R., Strominger J.L. Purification and characterization of class II histocompatibility antigens from a homozygous human B cell line. J Biol Chem. 262:1987;16087
12. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 72:1976;248
13. Wiesmüller KH, Feiertag S, Fleckenstein B, Kienle S, Stoll D, Hermann M, Jung G: Automated procedures for the production and analysis of complex peptide libraries. In Jung G (ed): Combinatorial Peptide and Nonpeptide Libraries. Weinheim, Verlag Chemie, 1996
14. Stevanović S., Jung G. Multiple sequence analysis pool sequencing of synthetic and natural peptide libraries. Anal Biochem. 212:1993;212
15. Metzger J.W., Kempter C., Wiesmüller K.H., Jung G. Electrospray mass spectrometry and tandem mass spectrometry of synthetic multicomponent peptide mixtures determination of composition and purity. Anal Biochem. 219:1994;261
16. Jung G., Beck-Sickinger A.G. Multiple peptide synthesis methods and their applications. Angew Chem Int Ed Engl. 31:1992;367
17. Tompkins S.M., Rota P.A., Moore J.C., Jensen P.E. A europium fluoroimmunoassay for measuring binding of antigen to class II MHC glycoproteins. J Immunol Methods. 163:1993;209
18. Fleckenstein B., Kalbacher H., Muller C.P., Stoll D., Halder T., Jung G., Wiesmüller K.H. New ligands binding to the human leukocyte antigen class II molecule DRB1*0101 based on the activity pattern of an undecapeptide library. Eur J Biochem. 240:1996;71
19. Fleckenstein B., Jung G., Wiesmüller K.H. Quantitative analysis of peptide-MHC class II interaction. Semin Immunol. 11:1999;405
20. Falk K., Rötzschke O., Stevanović S., Jung G., Rammensee H.G. Pool sequencing of natural HLA-DR, DQ, and DP ligands reveals detailed peptide motifs, constraints of processing, and general rules. Immunogenetics. 39:1994;230
21. Khalil-Daher I., Boisgerault F., Feugeas J.P., Tieng V., Toubert A., Charron D. Naturally processed peptides from HLA-DQ7 (α1*0501- β1*0301) influence of both alpha and beta chain polymorphism in the HLA-DQ peptide binding specificity. Eur J Immunol. 28:1998;3840
22. Lee K.H., Wucherpfennig K.W., Wiley D.C. Structure of a human insulin peptide-HLA-DQ8 complex and susceptibility to type 1 diabetes. Nat Immunol. 2:2001;501
23. van de Wal Y., Kooy Y.M., Drijfhout J.W., Amons R., Papadopoulos G.K., Koning F. Unique peptide binding characteristics of the disease-associated DQ(α1*0501, β1*0201) vs the non-disease-associated DQ(α1*0201, β1*0202) molecule. Immunogenetics. 46:1997;484
24. Vartdal F., Johansen B.H., Friede T., Thorpe C.J., Stevanović S., Eriksen J.E., Sletten K., Thorsby E., Rammensee H.G., Sollid L.M. The peptide binding motif of the disease associated HLA-DQ (α1* 0501, β1* 0201) molecule. Eur J Immunol. 26:1996;2764
25. Cucca F., Lampis R., Congia M., Angius E., Nutland S., Bain S.C., Barnett A.H., Todd J.A. A correlation between the relative predisposition of MHC class II alleles to type 1 diabetes and the structure of their proteins. Hum Mol Genet. 10:2001;2025
26. Nepom B.S., Nepom G.T., Coleman M., Kwok W.W. Critical contribution of beta chain residue 57 in peptide binding ability of both HLA-DR and -DQ molecules. Proc Natl Acad Sci USA. 93:1996;7202
27. Reizis B., Eisenstein M., Mor F., Cohen I.R. The peptide-binding strategy of the MHC class II I-A molecules. Immunol Today. 19:1998;212
28. Quarsten H., Paulsen G., Johansen B.H., Thorpe C.J., Holm A., Buus S., Sollid L.M. The P9 pocket of HLA-DQ2 (non-Aspβ57) has no particular preference for negatively charged anchor residues found in other type 1 diabetes-predisposing non-Aspβ57 MHC class II molecules. Int Immunol. 10:1998;1229
29. Johansen B.H., Jensen T., Thorpe C.J., Vartdal F., Thorsby E., Sollid L.M. Both alpha and beta chain polymorphisms determine the specificity of the disease-associated HLA-DQ2 molecules, with beta chain residues being most influential. Immunogenetics. 45:1996;142
30. Wedderburn L.R., Patel A., Varsani H., Woo P. Divergence in the degree of clonal expansions in inflammatory T cell subpopulations mirrors HLA-associated risk alleles in genetically and clinically distinct subtypes of childhood arthritis. Int Immunol. 13:2001;1541
31. Snijders A., Elferink D.G., Geluk A., Der Zanden A.L., Vos K., Schreuder G.M., Breedveld F.C., de Vries R.R., Zanelli E.H. An HLA-DRB1-derived peptide associated with protection against rheumatoid arthritis is naturally processed by human APCs. J Immunol. 166:2001;4987
32. Jung C., Kalbus M., Fleckenstein B., Melms A., Jung G., Wiesmüller K.H. New ligands for HLA DRB1*0301 by random selection of favourable amino acids ranked by competition studies with undecapeptide amide sublibraries. J Immunol Methods. 219:1998;139
33. Falcioni F., Ito K., Vidovic D., Belunis C., Campbell R., Berthel S.J., Bolin D.R., Gillespie P.B., Huby N., Olson G.L., Sarabu R., Guenot J., Madison V., Hammer J., Sinigaglia F., Steinmetz M., Nagy Z.A. Peptidomimetic compounds that inhibit antigen presentation by autoimmune disease-associated class II major histocompatibility molecules. Nat Biotechnol. 17:1999;562